AbbVie's Post-Humira Triumph: Skyrizi and Rinvoq Drive Sector-Leading Growth

Key Takeaways

• AbbVie's Q1 2026 results significantly exceeded revenue and adjusted EPS expectations, driven by strong demand for its immunology blockbusters Skyrizi and Rinvoq.
• This performance underscores a successful transition away from Humira's patent cliff, with management raising full-year 2026 guidance for both revenue and adjusted earnings per share.
• While the broader therapeutics sector saw a satisfactory Q1, AbbVie's specific growth drivers and pipeline advancements position it as a leader, reflected in its substantial post-earnings stock rally.

The Humira Hand-Off: AbbVie's Pivotal Q1 2026

AbbVie Inc. (NYSE: ABBV) has been navigating one of the pharmaceutical industry's most closely watched patent cliffs: the decline of its former top-seller, Humira. The company's first-quarter 2026 earnings, reported on April 29, 2026, provided a definitive answer to investor anxieties, showcasing a robust performance that not only beat expectations but also solidified the success of its strategic pivot. Trading at $261.07 as of July 2, 2026, AbbVie has seen its market capitalization swell to $461.26 billion, with shares climbing significantly since the Q1 report. This surge, including a 31.6% rise since earnings were announced, highlights a market increasingly confident in AbbVie's future beyond its legacy drug. The question now is whether this momentum is sustainable, especially when viewed against the backdrop of a generally strong therapeutics sector.

Financial Strength in Transition

AbbVie's Q1 2026 financial results painted a picture of resilience and strategic execution. The company reported adjusted earnings per share (EPS) of $2.65, surpassing the Zacks Consensus Estimate of $2.62 and exceeding its own guidance of $2.56-$2.60. This represented a healthy 7.7% year-over-year increase in adjusted EPS. On the top line, revenues reached $15.0 billion, beating the Zacks Consensus Estimate of $14.78 billion and the company's guidance of $14.70 billion. This marked a 12.4% year-over-year increase on a reported basis, or 10.3% operationally. Despite a GAAP diluted EPS of $0.39, a 45.8% decrease from the prior year, the adjusted figures, which account for acquired IPR&D and milestone expenses, underscore the underlying operational strength.

The company's adjusted operating margin for the quarter stood at 40.8%, which included a 5% unfavorable impact from acquired IPR&D expenses. Looking ahead, AbbVie raised its full-year 2026 adjusted EPS guidance to a range of $14.08-$14.28, up from the previous $13.96-$14.16. Total revenue guidance for 2026 was also increased to $67.3 billion from $67 billion. This upward revision reflects management's confidence in the continued performance of its key growth drivers.

The Immunology Engine: Skyrizi and Rinvoq Take the Lead

The true engine behind AbbVie's Q1 outperformance was its immunology portfolio, which generated $7.29 billion in global net revenues, marking a 16.4% reported increase year-over-year. Within this segment, Skyrizi and Rinvoq have firmly established themselves as the successors to Humira. Skyrizi (risankizumab) posted Q1 sales of $4.48 billion, surging 30.9% year-over-year and comfortably beating analyst estimates. This growth was driven by strong demand in psoriatic and IBD indications, with management expecting full-year 2026 revenues for Skyrizi to reach $21.6 billion.

Similarly, Rinvoq (upadacitinib) generated $2.12 billion in Q1 sales, up 20.2% operationally, also exceeding consensus expectations. Rinvoq's success stems from strong demand across its approved indications, including rheumatoid arthritis and inflammatory bowel disease, where it is gaining significant patient share. AbbVie expects Rinvoq revenues to reach $10.2 billion for the full year 2026.

This robust performance from Skyrizi and Rinvoq effectively offsets the anticipated decline of Humira, which saw its global sales fall 40.3% to $688 million in the quarter due to biosimilar competition. While Humira's sales missed the Zacks Consensus Estimate of $697 million, this decline is largely priced into AbbVie's strategy, with full-year 2026 Humira revenues projected at $2.9 billion. The successful pivot highlights AbbVie's ability to innovate and commercialize new blockbusters, a critical capability in the competitive biopharmaceutical landscape.

Beyond Immunology: Neuroscience and Oncology Contributions

While immunology dominated the headlines, AbbVie's neuroscience portfolio delivered a strong performance, with sales rising 24.3% to $2.88 billion in Q1. This segment's growth was fueled by key products like Botox Therapeutic, which crossed the $1 billion quarterly milestone for the first time with sales of $1.01 billion, an increase of 14.9%. Vraylar sales increased 18.4% to $905 million, driven by prescription growth in both major depressive disorder and bipolar disorders. Migraine drugs Ubrelvy and Qulipta also contributed significantly, with sales up 41.2% to $339 million and 51.3% to $296 million, respectively. The global launch of Vyalev, which saw sales of $201 million, further bolstered the segment. AbbVie now expects neuroscience global sales to reach $12.6 billion in 2026, a slight increase from prior expectations.

In oncology/hematology, sales fell 3% to $1.63 billion, primarily due to a 24.7% decline in Imbruvica sales to $556 million. However, this was partially offset by rising Venclexta sales and contributions from newer drugs like Elahere and Epkinly. The oncology segment still managed to beat the Zacks Consensus Estimate of $1.57 billion, indicating underlying strength in other areas. AbbVie is actively expanding its oncology pipeline, with positive Phase 3 results for Epcoritamab in diffuse large B-cell lymphoma announced in late June 2026, signaling continued investment in next-generation cancer therapies.

A Sector in Flux: AbbVie's Relative Strength

The broader therapeutics sector experienced a satisfactory first quarter, with 11 tracked stocks reporting average revenue beats of 14.5% against consensus estimates. This positive sentiment translated into an average share price increase of 18.9% for these stocks since their latest earnings reports. However, performance varied significantly among individual players.

For instance, Moderna (NASDAQ: MRNA) led the pack with a remarkable 260% year-over-year revenue growth to $389 million, outperforming analyst expectations by 55.8%, and its stock surged 75.2%. In contrast, United Therapeutics (NASDAQ: UTHR) saw revenues decline 1.6% to $781.5 million, missing estimates by 1.9%, and its stock fell 3%.

Other large pharmaceutical companies also reported mixed results. Johnson & Johnson (NYSE: JNJ) delivered Q1 revenues of $24.06 billion, up 9.9% year-over-year, and raised its full-year 2026 outlook. Bristol Myers Squibb (NYSE: BMY) reported revenues of $11.489 billion, a 3% increase, but non-GAAP EPS declined 12%. Gilead Sciences (NASDAQ: GILD) saw total revenues rise 4% to $7.0 billion, with product sales excluding Veklury up 8%.

AbbVie's 12.4% reported revenue growth and 7.7% adjusted EPS growth position it favorably within this diverse landscape. Its ability to successfully transition away from Humira, driven by the strong performance of Skyrizi and Rinvoq, highlights a company executing its strategy effectively amidst competitive pressures and patent expirations. This focused growth, particularly in immunology and neuroscience, allows AbbVie to stand out even in a generally positive sector.

The Bear Case: Navigating Headwinds and Competition

Despite AbbVie's strong Q1 performance, several risk vectors warrant attention. The most significant is the ongoing impact of biosimilar competition on Humira, which is expected to continue its steep decline, with full-year 2026 revenues projected at just $2.9 billion. While Skyrizi and Rinvoq are successfully picking up the slack, any slowdown in their growth or unexpected competitive threats could pressure AbbVie's top line. The company already anticipates a low single-digit pricing headwind for both Skyrizi and Rinvoq in 2026 and over the next few years, which could temper future revenue expansion.

Another factor is the impact of acquired IPR&D and milestone expenses. The Q1 2026 adjusted operating margin of 40.8% included a 5% unfavorable impact from these charges, and the full-year adjusted operating margin guidance was lowered to 47.5% from 48.5% due to a roughly 1% unfavorable impact from IPR&D incurred through Q1. These charges, while necessary for pipeline development, can create volatility in reported earnings and margins.

Furthermore, competition in key therapeutic areas remains fierce. In psoriasis, for instance, Skyrizi's 30.9% growth came despite Johnson & Johnson receiving FDA approval in March 2026 for Icotyde, a new oral psoriasis pill that directly competes in the IL-23 class. While AbbVie management expressed confidence in navigating this competition, the introduction of new, effective treatments by rivals could intensify pricing pressure and market share battles. Macroeconomic headwinds, though not explicitly detailed, were also cited by management as ongoing challenges, suggesting a cautious outlook despite strong internal performance.

Analyst View: Consensus and Upside Potential

Wall Street analysts have largely reacted positively to AbbVie's Q1 2026 results and its raised full-year guidance. The consensus adjusted EPS estimate for Q2 2026 stands at $3.77, with projections accelerating through the second half of the year to approximately $3.85 for Q3 and $3.99 for Q4. This trajectory reflects confidence in the company's growth drivers and its ability to manage the post-Humira transition.

The stock's significant rally since the Q1 earnings report, with shares up 31.6% to $260.14 by July 3, 2026, indicates strong investor sentiment. While specific analyst price targets from multiple firms are not uniformly available, the TIKR blog noted a potential "road to $311" for AbbVie stock, implying a substantial upside from current levels. This suggests a median implied upside of approximately 19% from the current price of $261.07. The Zacks Investment Research currently assigns AbbVie a Zacks Rank #3 (Hold), indicating an expectation of in-line returns over the next few months, which might be a more conservative stance compared to the market's recent enthusiasm.

The Verdict

AbbVie's Q1 2026 earnings unequivocally demonstrate the success of its strategic pivot away from Humira, driven by the exceptional growth of Skyrizi and Rinvoq. This performance, coupled with a robust neuroscience portfolio and a raised full-year outlook, positions AbbVie as a compelling investment in the pharmaceutical sector. While competitive pressures and IPR&D charges present headwinds, the company's strong pipeline and commercial execution are proving resilient.

For investors looking to capitalize on this momentum, an entry zone for ABBV shares between $255 and $260 would be prudent, allowing for a slight pullback from recent highs. Our 12-month target price for AbbVie is $311, reflecting the continued growth of its key immunology and neuroscience assets and the market's increasing confidence in its long-term trajectory. An invalidation level below $230 would signal a breakdown in the core growth thesis, suggesting that competitive pressures or pipeline setbacks are more significant than currently anticipated. AbbVie's post-Humira era is not just surviving; it's thriving.

---

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.